study question: Is treatment with corifollitropin alfa, a new recombinant gonadotrophin with sustained follicle-stimulating activity, safe in terms of perinatal complications and birth defects in infants conceived following corifollitropin alfa treatment for contolled ovarian stimulation (COS)?
Introduction
The health of children born following assisted reproduction technology (ART) using any new procedures or compounds is paramount. Any concerns about the safety of these procedures/compounds may be allayed by evaluating the risk of perinatal complications or birth defects. Obviously, ovarian stimulation protocols for IVF/ICSI should not compromise the health of the mother during pregnancy or the infants born to these mothers (Ericson and Källén, 2001; Anthony et al., 2002; Bonduelle et al., 2002; Hansen et al., 2002) .
To date, there have been no reports that specific drugs used in ART programmes increase these potential risks. However, it has been documented that IVF/ICSI children have an increased risk (relative risk of 1.3) of major malformations, especially cardiac malformations (Wen et al., 2010; Tararbit et al., 2011) , when compared with the general population (Sutcliffe and Ludwig, 2007) . The reason for this increased risk is not fully understood but may be related to the underlying cause of the infertility of the parents (Zhu et al., 2006) .
Corifollitropin alfa is a novel recombinant gonadotrophin, used to induce multifollicular development prior to IVF or ICSI, with high specific affinity for the FSH receptor . Its FSH receptor binding specificity and activation are comparable with that of recombinant FSH (rFSH) and it lacks intrinsic activity for the LH receptor and the thyroid-stimulating hormone receptor (Verbost et al., 2011) . Therefore, it may be assumed that the risks associated with corifollitropin alfa treatment for women trying to achieve a pregnancy and their offspring are comparable with those associated with rFSH treatment, but this assumption is unproved.
Two large-scale, prospective, multinational, double-blind, randomized Phase III trials have confirmed the effectiveness of one injection of corifollitropin alfa for the first 7 days of controlled ovarian stimulation (COS) compared with daily rFSH injections in achieving good ongoing pregnancy rates in a GnRH antagonist protocol Corifollitropin Alfa Ensure Study Group, 2010) .
Analyses of these two comparative randomized controlled trials (RCTs) may be considered most valid when comparing corifollitropin alfa with daily FSH because the same double-blind protocol design was followed and the same inclusion/exclusion criteria used with the exception of body weight. In the two recommended body weight categories, the two dosages were also shown to provide equal exposure and the same ovarian response (Ledger et al., 2011) .
In addition, the current investigation is a follow-up of all fetuses and infants from two comparative RCTs with corifollitropin alfa versus rFSH, and all Phase II and III trials with corifollitropin alfa intervention.
Materials and Methods

Follow-up of Phase III RCTs
Two follow-up protocols (NCT00703014 and NCT00702624) collected the safety follow-up data of neonatal outcomes from two Phase III, double-blind, RCTs (see Table I ), Engage (NCT00696800) and Ensure (NCT00702845) trials have been described previously Corifollitropin Alfa Ensure Study Group, 2010 Patients received a single injection of corifollitropin alfa (Elonva, w N.V. Organon, The Netherlands) in a dose of 100 or 150 mg during the first 7 days of COS. Patients were recruited using identical inclusion and exclusion criteria with the exception of body weight: patients in the Engage trial weighed ≥60 kg (N ¼ 1506) and patients in the Ensure trial weighed ≤60 kg (N ¼ 396). All patients were treated from stimulation Day 5 onward with a GnRH antagonist, and ovarian stimulation was initiated in the Engage trial with either 150 mg corifollitropin alfa or daily 200 IU rFSH (treatment ratio: 1:1) and in the Ensure trial with 100 mg corifollitropin alfa or 150 IU rFSH (treatment ratio: 2:1). Apart from these differences in dosages according to body weight, the treatment regimens were identical. All subjects with an ultrasonically confirmed ongoing pregnancy of at least 10 weeks after embryo transfer were eligible for enrolment in the pregnancy and neonatal follow-up study. The studies were approved by the local health authorities and the independent medical ethics committee of each study centre, and all patients had to provide informed consent to participate in this follow-up study. Pregnant patients only completed the trial if the examination of the newborns at 4 -12 weeks' post-partum was completed.
Follow-up on other Phase II and III trials
Data on fetal and neonatal outcomes were also collected from eight international trials, five Phase II and three Phase III trials with corifollitropin alfa intervention (see Table I ). Patients received corifollitropin alfa in doses ranging from 7.5 to 240 mg during the first 7 days of COS. The following other trials included were: (i) NCT 00702585 (pregnancy and infant follow-up trial NCT 00702195) was a randomized, double-blind, placebo-controlled, comparative trial to investigate the optimal dose of a single administration of corifollitropin alfa (7.5, 15 and 30 mg) to induce monofollicular ovulation in women with World Health Organization (WHO) Group II anovulatory infertility (Balen et al., 2004 
Data collection
Information was collected prospectively on pregnancy outcome, mode of delivery and neonatal characteristics (gestational age, gender, weight, length, head circumference and Apgar score). All adverse events (AEs) and serious AEs (SAEs) in the infants were recorded after assessment by the infant's physician at birth and at follow-up 4 -12 weeks postpartum. All SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA, version 12.0) to enable analysis by organ system. Any congenital abnormality was recorded as a SAE. All AEs and SAEs were adjudicated by an independent medical expert as being either major or minor congenital malformations according to the broad classification. Major malformations were defined as any congenital malformation that causes functional impairment or requires surgical correction (broad definition; Bonduelle et al., 2002) . In this follow-up project, the definition of major malformation also included inguinal hernia for children born after 36 weeks of gestation, patent ductus arteriosus (if the ductus was still patent after 3 months for children born at term or after 6 months for children born before 36 weeks of gestation), atrium septum defect type I (type ostium primum), hypospadias if the meatus was not glandular, pyloric stenosis, inherited diseases and chromosomal anomalies. Minor malformations were defined as any congenital malformation not classified as major.
Statistical analysis
Characteristics of live born infants were summarized by treatment group using means and SDs for continuous variables and frequencies and percentages for categorical variables.
All statistical analyses were performed for the two RCTs unless stated otherwise. Continuous characteristics were compared between treatment groups using an analysis of variance correcting for protocol and pregnancy type (singleton versus multiple). Categorical characteristics were compared using the Cochran -Mantel-Haenszel test stratified for protocol and pregnancy type. P-values were reported only if ,0.05.
AEs classified as major congenital malformation were coded using MedDRA. More specifically, these AEs were 'mapped' to preferred terms (PTs), which, in turn, were mapped to high-level group terms (HLGTs) to enable further analysis by organ class. The incidence of AEs classified as major congenital malformation was summarized by HLGT, PT and treatment group.
Corifollitropin alfa to rFSH odds ratios (ORs) and corresponding 95% confidence intervals (CIs) for major (respectively, any) congenital malformation were obtained using the Cochran-Mantel -Haenszel method stratified for protocol and pregnancy type. With 440 and 381 fetuses in the corifollitropin alfa and rFSH group, respectively, there was close to 80% power to detect a doubling of the incidence of major malformations (i.e. from 5 to 10%), using a 0.05 two-sided significance level.
Results
Comparative follow-up data from RCTs
Evolution of pregnancies
From the RCTs, 342 women with ongoing pregnancies at 10 weeks who had received corifollitropin alfa during the first 7 days of COS and 312 women in the comparator arm who had received rFSH were enrolled in the follow-up study. The evolution of ongoing pregnancies and number of live born infants in the corifollitropin alfa and rFSH arms of the RCTs are presented in Table II . In total, 302 (88.3%) mothers with 383 (87.0%) infants in the corifollitropin alfa group and 280 (89.7%) mothers with 339 (89.0%) infants in the rFSH group completed the follow-up including the examination of their newborns at 4-12 weeks after birth.
At week 10 of gestation, there were 247 (72.2%) and 243 (77.9%) singletons in the corifollitropin alfa and rFSH group, respectively, whereas the incidence of multiple pregnancies was 95 (27.8%) and 69 (22.1%), respectively, and this difference was not statistically significant. There were three triplet pregnancies in the corifollitropin group which all resulted from the transfer of excellent (Grade 1) embryos; in one case only one embryo was replaced on Day 5 which resulted in one gestational sac, in one case two excellent embryos were replaced on Day 5 resulting in three gestational sacs and in the last case two embryos were replaced at Day 3 and resulted in two gestational sacs.
In total, 6 (1.4%) and 4 (1.0%) ongoing pregnancies terminated at 10-20 weeks in the corifollitropin alfa and rFSH groups, respectively. The incidence of intrauterine death/stillbirth (≥20 weeks of gestation) was 1.9% (n ¼ 8) in corifollitropin alfa-treated patients and 0.5% (n ¼ 2) in rFSH-treated patients. The incidence was 0.8% in singleton pregnancies and 3.2% in multiple pregnancies after treatment with corifollitropin alfa and, respectively, 0.8 and 0.0% after treatment with rFSH. This resulted in 332/342 (97.1%) pregnancies with a live born infant in the corifollitropin alfa group and 304/312 (97.4%) in the rFSH group. From the 440 fetuses at 10 weeks after embryo transfer in the corifollitropin alfa group, there were 424 (96.4%) live born infants and from 381 fetuses in the rFSH arm there were 370 (97.1%) live born infants.
Neonatal outcome of live born infants
In both treatment groups, most infants were delivered by elective or emergency Caesarean section (54 and 50% in the corifollitropin alfa and rFSH groups, respectively). The percentage of infants delivered vaginally and requiring obstetric assistance via induction, forceps delivery and vacuum extraction was similar in both treatment groups. Gestational age, gender, birthweight, length, head circumference and Apgar scores of live born infants at birth are summarized in Table III . Data are also given separately for singleton and multiple births (see also Supplementary data, Table S1 and Figure S1 for data by trial and treatment group differences and OR). There were no notable differences in these characteristics between the corifollitropin alfa and rFSH groups and none of the differences were statistically significant.
The overall incidence of AEs in live born infants was similar between treatments, 47.4% in the corifollitropin alfa group and 50.8% in the rFSH group (P ¼ 0.35). The frequency of infant premature birth (gestational age ≤37 weeks) was similar in both maternal treatment groups (27.8 and 25.7% of live born infants in the corifollitropin alfa and rFSH maternal groups, respectively) and the proportions of infants with low birthweights and very low birthweights or with low Apgar scores were comparable, as shown in Table IV , where none of the differences were statistically significant (see also Supplementary data, Table S2 and Figure S2 for data by trial and treatment group OR). Data are also given separately for singleton and multiple births. Neonatal deaths were reported for 8/424 (1.9%) and 6/370 (1.6%) of live born infants in the corifollitropin alfa and rFSH groups, respectively. rFSH, recombinant FSH. All percentages were based on the number of ongoing pregnancies at 10 weeks.
a Enrolled in the follow-up trial.
Congenital malformations
The incidence of any or major congenital malformation (according to the broad definition) detected among live born infants is presented in Table V (see also Supplementary data, Table S3 and Figure S3 for data by trial and treatment group OR and Supplementary data, Table S4 ). The incidence of any malformation was 16.3% in the corifollitropin alfa maternal treatment group and 17.0% in the rFSH treatment group and statistical analysis showed no significant difference between the treatment groups (OR, 0.94; 95% CI, 0.65 -1.37). 
Premature births a 0.71; 95% CI, 0.36 -1.38). In singleton births, the rates of major malformations were 2.9 and 5.1% in the corifollitropin alfa and rFSH groups, respectively, and in multiple births these rates were 5.5 and 6.1%, respectively. The incidence of congenital malformations in all fetuses with cardiac activity at 10 weeks after embryo transfer (including fetuses of pregnancies that were spontaneously or medically terminated) was similar to that of live born infants (any malformation, 16.1% in the corifollitropin alfa maternal treatment group and 17.6% in the rFSH treatment group; major malformations, 4.3 and 6.3% in the corifollitropin alfa and rFSH groups, respectively). Hydrops fetalis and congenital hydrocephalus were reported for spontaneously or medically terminated fetuses in the corifollitropin alfa group. In the rFSH group, anencephaly and ventricular septal defect were reported in one fetus and hydrops fetalis, trisomy 21 and renal aplasia were reported in three subsequent cases. All major malformations in live born infants in the RCTs are listed in Table VI showing data for the corifollitropin alfa group and rFSH group separately (see also Supplementary data, Table S5 for major malformations by MedDRA high-level group and PT). In both maternal treatment groups, the reported major malformations were most frequently cardiac and vascular congenital disorders (2.4% for the corifollitropin alfa group and 2.7% for the rFSH group) and gastrointestinal tract congenital disorders (0.9% as major for the corifollitropin alfa group and 1.1% for the rFSH group). Antral septal defects were the only specific major malformations occurring in .1% of infants in either maternal treatment group (0.7% in the corifollitropin alfa group and 1.6% in the rFSH group).
In the corifollitropin alfa and rFSH groups, respectively, the most commonly reported congenital minor malformations were cardiac and vascular disorders (3.1 and 4.9%), musculoskeletal and connective tissue disorders (2.6 and 2.2%), gastrointestinal tract disorders (2.1 and 1.1%), eye disorders (1.2 and 1.4%), skin and subcutaneous tissue disorders (1.2 and 1.1%) and renal and urinary tract disorders (0 and 1.1%).
Combined follow-up data after corifollitropin alfa treatment including all Phase II and III trials
Evolution of pregnancies
Pooling all Phase II and III trials (including Engage and Ensure), 677 pregnant women with 838 fetuses with cardiac activity at 10 weeks after embryo transfer and 806 live births were followed up for safety evaluation, as shown in Tables I and II . In total, 602 (88.9%) mothers with 735 (87.7%) infants completed the follow-up, including the examination of their newborns at 4-12 weeks after birth.
Ongoing pregnancies ≥10 weeks included 522 (77.1%) singleton and 155 (22.9%) multiple pregnancies. In total, 15 (1.8%) ongoing pregnancies terminated at 10-20 weeks and the incidence of intrauterine death/stillbirth (≥20 weeks of gestation) was 1.4% (n ¼ 12). This resulted in 655 (96.8%) pregnancies with at least one live born infant. From 838 fetuses at 10 weeks after embryo transfer following corifollitropin alfa treatment, there were 806 (96.2%) live born infants.
Neonatal outcome of live born infants
Gestational age, gender, birthweight, length, head circumference and Apgar scores of all live born infants are also summarized in Table III . The overall incidence of AEs was 43.2% (35.7% in singleton pregnancies and 55.9% in multiple pregnancies). The incidence of neonatal deaths was 2.0%.
Congenital malformations
The incidence of any congenital malformation (according to the broad definition) detected among all live born infants was 14.5% (13.0% in singletons and 17.1% in multiples, see Table VII ) and 15.0% in all fetuses with heart beat activity at 10 weeks.
For the nine fetuses that were spontaneously or medically terminated, the following congenital malformations were reported: kidney malformation, Ebstein's anomaly, hydrops fetalis and congenital hydrocephalus, trisomy 21, trisomy 18, cystic lymphangioma, talipes. For one fetus multiple congenital malformations were reported: solitary kidney, cleft palate, renal dysplasia, skull malformation, congenital pulmonary artery anomaly and pulmonary malformation.
Major malformations (according to the broad definition) were reported in 4.5% of live born infants, 2.8 and 7.4% in singletons and multiple births, respectively. From all fetuses with cardiac activity at 10 weeks after embryo transfer, there were 5.4% major malformations. The major malformations in live born infants from all corifollitropin alfa intervention trials are listed in Table VI ; the most frequently recorded major malformations did occur in the organ system classes of cardiac and vascular disorders, and gastrointestinal tract disorders (see also Supplementary data, Table S5 for expansion of categories).
Discussion
In this study, the infant follow-up data from two large RCTs showed that the health of 424 live born infants conceived after treatment with a single dose of corifollitropin alfa during the first 7 days of COS was no different from that of 370 live born infants conceived after COS with daily rFSH. There were no treatment-related differences in neonatal characteristics or in the incidence of major or minor malformations. The live birth rates, mode of delivery, number of premature births and premature births with low birthweights, congenital malformations and stillbirths or neonatal deaths were similar between the treatment groups. The safety data from the two large RCTs are supported and strengthened by the infant follow-up data, from 806 infants, following all trials to date with maternal corifollitropin alfa treatment. The incidence of major malformations in live born infants in the RCTs (4.0% in the corifollitropin alfa group and 5.4% in the rFSH group) was comparable with the incidence when all trials with corifollitropin alfa intervention were included (4.5%).
The incidence and type of major malformations with the corifollitropin alfa therapy in the current study was comparable with the 5% incidence reported in a large study including 1000 fetuses following maternal COS with rFSH in a GnRH antagonist (ganirelix) protocol using the same methodology and definitions (Bonduelle et al., 2010) .
The definition of a major malformation, which may vary between studies, influences its absolute incidence which then may vary between 1 and 10% (Rimm et al., 2004) . In addition to the definition, Infant follow-up on safety of corifollitropin alfa the number of observations, the duration of follow-up after birth, the incidence of multiple pregnancies and the thoroughness of the examination are other determining factors. Care should be taken when comparing the incidence of major malformations between different prospective studies or even population surveillance data, as the latter is often hampered by underreporting (Simpson, 1996) . Taking into account any malformation, thus both major and minor malformations, the overall incidence was 16 -17% and similar in both treatment groups. This incidence may be considered relatively high but is known to be related to the thoroughness of paediatric examination as well as the awareness of physicians participating in a prospective trial to collect malformations after exposure to a new fertility drug (Leppig et al., 1987) .
In the current RCTs, the incidence of multiple pregnancies tended to be higher in patients treated with corifollitropin alfa (43.2%) than in patients treated with rFSH (35.9%), whereas the average number (maximal two) of embryos replaced was similar in both arms of the trials. This difference included three triplets in the corifollitropin alfa arm versus none in the rFSH arm. The occurrence of a monozygotic triplet after replacement of a single embryo is rare, and in general, the occurrence of monozygotic multiples is thought to be related to prolonged culture (Chang et al., 2009; Knopman et al., 2010) .
The incidence of intrauterine death/stillbirths at ≥20 weeks and neonatal deaths in women treated with corifollitropin alfa for COS (1.5 and 2.0%, respectively, in the current analysis of all trials) was comparable with previously reported data in a large cohort of women undergoing COS for ICSI or IVF (stillbirths of 1.5% and neonatal deaths of 1.1%; Bonduelle et al., 2002) and in the GnRH antagonist arm of the 2010 Bonduelle study (stillbirths of 1.5% and neonatal deaths of 1.2%; Bonduelle et al., 2010) .
The data from the current prospective RCTs are reassuring. Despite previous reassuring reports on obstetric and neonatal complications and congenital abnormalities after ART (Ericson and Källén, 2001; Boerrigter et al., 2002; Anthony et al., 2002; Bonduelle et al., 2002; Nygren et al., 2007) , the debate continues about the safety of ART for children, and the ways in which safety is evaluated. Concerns about the limitations of commonly used methods of assessment (including lack of appropriate comparison (control) groups, failure to take into account potential confounding variables and differences in the criteria used to evaluate anomalies in the ART population versus the general population) have prompted calls for more rigorous evaluation, including prospective surveillance of congenital abnormalities (Simpson, 1996) and a hesitancy to dismiss observed increases in the risk of adverse outcomes found in literature reviews (Kurinczuk, 2003; Hansen et al., 2005; Reefhuis et al., 2009) .
In conclusion, the current neonatal follow-up data, including comparative data of 440 fetuses and overall data of 838 fetuses conceived after maternal treatment with corifollitropin alfa, further support the safety of this new treatment option in IVF. 
